ArticleChemMedChem2026
Bacterial Ghosts as Innovative Transport Vehicles for Platinum-Based Anticancer Drugs.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cisplatin, carboplatin, and oxaliplatin (OXA) are widely used platinum-based anticancer drugs, but their clinical application is limited by severe adverse effects, including nephrotoxicity, ototoxicity, and neurotoxicity, as well as drug resistance. Oxaliplatin (Eloxatin) is the only platinum compound showing superior clinical efficacy in the treatment of colorectal cancer, yet its use is restricted by dose-dependent toxicity. To address these limitations, OXA and four derivatives were loaded into bacterial ghosts (BGs) as novel drug carriers. BGs derived from the nonpathogenic strains Escherichia coli Nissle 1917 (EcN) and Escherichia coli NM522 (Ec NM522) were loaded by simple resuspension and incubation. Platinum content was quantified by inductively coupled plasma mass spectrometry, while the physicochemical properties of the formulations were characterized by fast protein liquid chromatography, transmission and scanning electron microscopy, electron energy-loss spectroscopy, and flow cytometry. The stability of OXA-loaded BG formulations was evaluated in different media and under various storage conditions for up to 120 days. The formulations demonstrated high batch-to-batch reproducibility, and bacterial encapsulation preserved the in vitro anticancer activity of the platinum compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.